BioSpace News Archive

COUR Pharmaceuticals, a biotechnology company developing novel immune-modifying nanoparticles to treat immune disorders, announced the appointment of Brian C. Bock as the Company’s new Chief Financial Officer.

Kazia Therapeutics Limited is pleased to announce that a phase II study of Kazia’s investigational new drug, paxalisib, in combination with metformin and a ketogenic diet for the treatment of newly diagnosed and recurrent glioblastoma, has been initiated at Weill Cornell Medicine, with the first patient successfully initiated in the study and a second patient already in screening.

Heska Corporation reported financial results in two segments (North America and International) for its fourth quarter and full year ended December 31, 2021.

InVera Medical are delighted to announce the publication of its pre-clinical feasibility study of the InVera minimally invasive, exclusively mechanical venous ablation device in Phlebology, an official journal of several international venous societies.

Blueprint Medicines Corporation (NASDAQ: BPMC) and Proteovant Therapeutics today announced a strategic collaboration to advance novel targeted protein degrader therapies to address important areas of medical need.

Seelos Therapeutics, Inc. today announced the dosing of the first participants in its registrational Phase II/III trial studying the investigational treatment SLS-005.

AbbVie (NYSE: ABBV), today announced the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for IMBRUVICA®.

Chiesi Global Rare Diseases announced the release of a white paper titled, “The Burden of Rare Diseases: An Economic Evaluation,” based on results from a study conducted with support from IQVIA, a leading global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry.

In honor of Rare Disease Day on February 28 and the 25-30 million Americans living with rare diseases,1 the Janssen Pharmaceutical Companies of Johnson & Johnson announced the launch of the refreshed iMaGineMyMG, a national campaign aimed to increase awareness of myasthenia gravis, a chronic autoimmune neuromuscular disorder, and provide support to people living with the condition.

Freenome, a privately held biotech company, today announced the initiation of Vallania, a clinical study for the refinement and further development of its multiomics platform to detect multiple cancers.